权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Neuropharmacology Core

神经药理学核心

基本信息

批准号：
10604270
负责人：
Sidney S Negus
金额：
$ 28.13万
依托单位：
VIRGINIA COMMONWEALTH UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-12-01 至 2025-03-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10604270
关键词：
Acute Address Analgesics Animals Area Behavior Behavioral Behavioral Assay Biological Assay Brain Brain region Center Core Grants Chronic Collaborations Collection Consultations Country Data Data Analyses Development Drug abuse Effectiveness Experimental Designs Family Funding Future G-Protein-Coupled Receptors Goals Grant Human Individual Institution Investigation Laboratories Leadership Measures Mediating Methodology Methods Microdialysis Molecular Molecular Target Neuroanatomy Neuropharmacology Neurotransmitters Nucleus Accumbens Opioid Pain Pathologic Pharmaceutical Preparations Pharmacotherapy Physiological Play Postdoctoral Fellow Procedures Psychological reinforcement Receptor Signaling Recording of previous events Research Research Personnel Research Project Grants Resources Rewards Scientist Self Administration Self Stimulation Serotonin Slice Substance Use Disorder Synthesis Chemistry System Techniques Tissues Training United States National Institutes of Health Universities Ventral Tegmental Area Virginia abuse liability awake behavioral study conditioned place preference drug action drug of abuse drug reward experience graduate student in vivo innovation meetings monoamine neural neurochemistry non-drug novel pre-clinical pre-clinical assessment receptor receptor binding receptor expression receptor function reinforcer substance use treatment tool

项目摘要

Project Summary – Neuropharmacology Core The Neuropharmacology Core is a new core that proposes to serve NIH-funded investigators affiliated with the P30 grant by increasing their access to key neurochemical and behavioral methodologies that are fundamental to advancement of preclinical drug abuse research. These methodologies will include techniques to assess expression and function of receptors in both tissue homogenates and tissue slices, in vivo microdialysis techniques to assess neurotransmitter levels in target brain areas in awake and behaving animals, and behavioral techniques to assess rewarding/reinforcing effects of drugs under different physiological or environmental conditions. Although this is a new core, the investigators have decades of expertise in their respective areas and a history of collaboration both with each other and with other VCU investigators. The rationale for this core is founded on the proposition that drugs of abuse act on molecular targets to modulate activity in brain reward systems and alter behavior, and preclinical drug abuse research benefits from coordinated investigation of drug effects along the entire continuum from molecular to behavioral levels of analysis. However, individual grants typically focus on a portion of this continuum and often lack resources for rapid and rational extension of important findings to other, related research domains. As one example, a synthetic chemistry grant might identify a new molecular entity with promising analgesic effects but lack resources for preclinical assessment of that compound's abuse liability or potential utility as a treatment for substance use disorders. As another example, a grant focused on behavioral studies to treat drug abuse might identify an effective medication strategy but lack resources to investigate candidate mechanisms that underlie medication efficacy. The Neuropharmacology Core proposes to address these gaps and strengthen the breadth and impact of drug abuse research at VCU. Studies of receptor expression and function (Aim 1), in vivo microdialysis (Aim 2), and behavioral expression of reward/reinforcement (Aim 3) will enable investigators to evaluate effects of pathological states or of acute/chronic drug treatments on neural systems and behavioral endpoints known to be important in drug abuse.

项目摘要-神经药理学核心神经药理学核心是一个新的核心，它提议为NIH资助的与通过增加他们获得基本的关键神经化学和行为方法的机会来获得P30赠款促进临床前药物滥用研究的进展。这些方法将包括评估受体在组织匀浆和组织切片中的表达及功能评估清醒和行为动物目标脑区神经递质水平的技术，以及评估药物在不同生理或心理状态下奖励/强化效果的行为技术环境条件。尽管这是一个新的核心，但调查人员在他们的以及彼此之间以及与其他VCU调查人员的合作历史。这一核心的理论基础是基于以下命题：滥用药物作用于分子靶标调节大脑奖励系统的活动并改变行为，临床前药物滥用研究受益于从分子水平到行为水平对药物影响的整个连续系统的协调研究分析。然而，个人赠款通常集中在这一连续体的一部分，而且往往缺乏资源用于将重要发现迅速、合理地扩展到其他相关研究领域。举个例子，一个合成化学奖可能确定一种新的分子实体，具有良好的止痛作用，但缺乏用于临床前评估该化合物的滥用倾向或治疗的潜在效用的资源物质使用障碍。作为另一个例子，一项专注于治疗药物滥用的行为研究的拨款可能会确定有效的用药策略，但缺乏资源来研究潜在的候选机制药物疗效。神经药理学核心建议解决这些差距，并加强 VCU药物滥用研究的广度和影响。受体表达和功能的研究(目标1)，in 活体微透析(目标2)和奖励/强化的行为表达(目标3)将使研究人员评估病理状态或急/慢性药物治疗对神经系统和行为的影响已知的终点在药物滥用中很重要。